Hughes David
Boston University School of Medicine, Boston, Massachusetts.
J Adv Pract Oncol. 2022 Apr;13(3):337-340. doi: 10.6004/jadpro.2022.13.3.32. Epub 2022 May 23.
Immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder characterized by the destruction of platelets and megakaryocytes. Its management has changed significantly in recent years, and at JADPRO Live Virtual 2021, David Hughes, PharmD, BCOP, reviewed the background and pathophysiology of ITP and clinical practice guidelines with an emphasis on patient preference when selecting first and subsequent lines of therapies in the chronic ITP setting.
免疫性血小板减少症（ITP）是一种获得性自身免疫性出血性疾病，其特征为血小板和巨核细胞的破坏。近年来，其治疗方法发生了显著变化。在2021年JADPRO现场虚拟会议上，药学博士、肿瘤药学委员会认证专家大卫·休斯回顾了ITP的背景和病理生理学以及临床实践指南，重点讨论了在慢性ITP情况下选择一线及后续治疗方案时患者的偏好。
